A study from endocrinologists and PCPs highlighted cost as a barrier to appropriate therapy for obesity, with PCPs more familiar with GLP-1 RAs than glucagon or GIP RAs. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.